MTS Health Partners LP
Mr. Goel has been at MTS Health Partners since 2013. During his time at MTS, he has advised on a number of life sciences transactions. Selected transactions include the sale of Colucid to Lilly, the sale of Celator to Jazz Pharmaceuticals, the sale of Strongbridge’s Macrilen to Novo Nordisk, the sale of Dimension to Ultragenyx, Eyepoint’s acquisition of Icon Biosciences, Strongbridge’s acquisition of Macrilen from Aeterna Zentaris, LFB S.A.’s joint venture with US WorldMeds, and the sale of PCT to Hitachi.
Prior to joining MTS Health Partners, Mr. Goel worked in the Strategy & Operations practice at Deloitte Consulting, where he advised clients in various industries including Healthcare. Mr. Goel has also worked at Red Oak Growth Partners, a private equity firm.
Mr. Goel has a Master of Business Administration (MBA) from the Graduate School of Business at Columbia University and a Bachelor of Science (BS) in Biomedical Engineering from Georgia Institute of Technology. He also serves as an advisor to Mount Sinai Innovation Partners.